A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects
Study Details
Study Description
Brief Summary
To evaluate the safety and immunogenicity of a combination of microparticulate monovalent HIV-1 MN synthetic branched peptide candidate vaccine for oral administration and monovalent HIV-1 MN synthetic branched peptide vaccine in alum for intramuscular administration in intermediate or higher risk HIV-negative volunteers.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1 |
Detailed Description
Volunteers receive one of two schedules of vaccines or placebo administered at days 0, 28, and 168. Specifically, group 1 receives oral microparticulate monovalent vaccine over 3 consecutive days on days 0, 1, and 2, and 28, 29, and 30, with the intramuscular monovalent vaccine given on day 168. Group 2 receives the intramuscular vaccine first, on day 0, followed by the oral form given on days 28, 29, and 30 and 168, 169, and 170. Volunteers are followed for 1 year.
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Inclusion Criteria
Volunteers must have:
-
Normal history and physical exam.
-
HIV negativity.
-
CD4 count >= 400 cells/mm3.
-
Intermediate or high risk sexual behavior or a history of injection drug use within 12 months prior to study entry.
-
Normal urine dipstick with esterase and nitrite.
Exclusion Criteria
Co-existing Condition:
Volunteers with the following symptoms or conditions are excluded:
-
Active tuberculosis.
-
Occupational or other responsibilities that would prevent completion of study.
Volunteers with the following prior conditions are excluded:
-
History of immunodeficiency, chronic illness, autoimmune disease, or use of immunosuppressive medications.
-
Psychiatric, medical, or substance abuse problems within the past 6 months that would affect ability to participate in study.
-
History of anaphylaxis or other serious adverse reactions to vaccines.
-
History of inflammatory gastrointestinal disease, celiac disease, or intestinal malignancy.
-
Acute gastroenteritis or gastrointestinal surgery within the past 12 months.
Prior Medication:
Excluded:
-
Live or attenuated vaccine within the past 60 days.
-
Illicit or experimental agents within the past 30 days. Intermediate or high risk sexual behavior. Injection drug use within the past 12 months.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Univ of California at San Francisco Gen Hosp | San Francisco | California | United States | 94110 |
Sponsors and Collaborators
- United Biomedical
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- 091
- UBI V106